Key points are not available for this paper at this time.
ABSTRACT Numerous issues and concerns are associated with current cancer therapeutics, such as multidrug resistance tumors, drug toxicity, severe side effects, and financial burden. Phytocompounds from plants have garnered significant interest as alternatives and adjunct therapies to mitigate these effects owing to their safety, efficacy, and cost‐effectiveness. As demonstrated by a number of preclinical and clinical investigations, phytocompounds and their combinations with doxorubicin mediate their anticancer effects by modulating multiple signaling pathways linked to immune system mobilization, apoptosis promotion, and inhibition of excessive cellular proliferation. However, these combinations continue to encounter challenges related to inadequate bioavailability, pharmacokinetics, and metabolism. To address these challenges, the utilization of different types of nanoparticles has become significant in nanomedicine for targeted drug delivery, enhancing bioavailability, pharmacokinetics, retention time, and reducing toxicity. This field of study showcases the remarkable amalgamation of nanotechnology with phytocompounds and chemo‐drugs (doxorubicin). Thus, this review focuses on recent developments in nanocarriers based drug delivery systems, particularly those intended for the simultaneous delivery of phytocompounds and doxorubicin chemotherapy medicines, by synthesizing existing knowledge and filling research gaps. This study also discussed the combined therapy of phytocompounds with doxorubicin chemotherapeutic drugs and other nanotechnology‐based carriers for cancer treatment.
Pandey et al. (Thu,) studied this question.